Semaglutide and NAION Vision Loss: The EMA Safety Finding

Semaglutide and NAION should no longer be described only as an emerging research signal. In June 2025, the European Medicines Agency's safety committee concluded that NAION is a very rare side effect of semaglutide medicines, including Ozempic, Rybelsus, and Wegovy.¹

That regulatory conclusion deserves clear reporting alongside the rarity of the event. It does not mean vision loss is common, establish a confirmed biological mechanism, or automatically apply the same classification to every GLP-1 medicine.

What NAION is

Non-arteritic anterior ischemic optic neuropathy, or NAION, is an optic-nerve condition associated with impaired blood supply and potentially serious vision loss. It is different from ordinary temporary visual fluctuation or every other cause of blurred vision. A clinician needs to evaluate the cause of a sudden change rather than identify it from a medication list alone.¹²

Existing diabetes and vascular-health differences also matter when researchers compare people taking different medicines. An observational association needs careful study because treatment groups can differ in ways beyond the prescription itself.

What EMA concluded

EMA reviewed clinical trials, post-marketing reports, medical literature, and other evidence. It recommended adding NAION to semaglutide product information as a very rare side effect, described as potentially affecting up to 1 in 10,000 people taking the medicine.¹

The agency also reported that epidemiological studies in adults with type 2 diabetes suggested approximately twice the risk compared with people not taking semaglutide. In absolute terms, it described about one additional case per 10,000 person-years of treatment.

Those two numbers answer different questions. A frequency category is not interchangeable with an excess incidence rate, and “twice the risk” does not mean a 50% chance of vision loss.

Why absolute risk matters

Imagine comparing two groups for a rare outcome. A relative increase can sound dramatic even when the number of additional cases is small. The absolute difference helps show the scale, while the relative comparison helps identify a possible treatment-related change.

Neither measure alone tells an individual exactly what will happen. Follow-up duration, the population studied, and how the event was identified all affect interpretation. A person-year combines how many people were followed with how long they were observed; it is not a lifetime-risk prediction.

What the Danish-Norwegian study contributes

A 2025 nationwide cohort study compared new semaglutide users with users of SGLT2 inhibitors in people with type 2 diabetes. It found an increased NAION risk associated with semaglutide, while emphasizing the low absolute risk.²

Using nationwide records helps investigate an uncommon event, but the study was observational. Statistical adjustment cannot guarantee that all differences between treatment groups have been removed. Its comparator and diabetes population also matter: it is not a randomized trial of every obesity-treatment option.

The study and EMA's broader assessment are complementary. Uncertainty about a precise mechanism or an individual risk estimate should not erase the regulatory finding; conversely, the finding should not be stretched into a claim that all GLP-1 products commonly cause blindness.

Sudden vision changes need urgent assessment

EMA advises people who develop sudden vision loss or rapidly worsening eyesight during semaglutide treatment to contact their doctor without delay. If NAION is confirmed, its recommendation is to stop semaglutide treatment.¹ That requires timely clinical evaluation and coordination with the prescriber, not waiting for the next routine refill.

Sudden vision change deserves urgent eye assessment even when someone is not taking semaglutide. Do not assume the medicine must be the cause, and do not delay care while trying to establish that connection yourself.

If an interruption follows clinical assessment, our stopping-treatment guide explains follow-up planning. Weight-regain concerns should not be used as a reason to postpone evaluation of an urgent symptom.

Discuss eye history before prescribing

Tell the clinician about previous NAION, other eye disease, diabetes care, and clinicians already managing your vision. Ask how the medicine's expected benefits and risks apply to your particular history. Our eligibility guide explains why a careful intake involves more than meeting a BMI threshold.

The semaglutide hub distinguishes its different brands and forms. Do not assume that a compounded preparation removes a molecule-related concern, or that choosing tirzepatide guarantees the absence of eye risk simply because this EMA decision concerns semaglutide.

Before paying for ongoing care, use the provider checklist to ask about clinician access and coordination. For a rare but potentially serious event, knowing how to reach appropriate care matters more than reassurance from a checkout questionnaire.